HER2 Support Group Forums - View Single Post - Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-der

Rich66 · 09-14-2008, 01:27 PM

Preparation of potent macrophage activating factors derived from cloned vitamin d binding protein and its domain and their therapeutic usage for cancer, hiv-infection and osteopetrosis

USPTO Application #: 20060014143
Title: Preparation of potent macrophage activating factors derived from cloned vitamin d binding protein and its domain and their therapeutic usage for cancer, hiv-infection and osteopetrosis
Abstract: Vitamin D-binding protein (Gc protein) and its small domain (approximately ⅕ of the Gc peptide also known as domain III) were cloned via a baculovirus vector. The cloned Gc protein and the cloned domain (Cd) peptide were treated with immobilized β-galactosidase and sialidase to yield macrophage activating factors, GcMAFc and CdMAF, respectively. These cloned macrophage activating factors and GcMAF are to be used for therapy of cancer, HIV-infection and osteopetrosis, and may also be used as adjuvants for [COLOR=blue ! important][COLOR=blue ! important]immunization[/COLOR][/COLOR] and vaccination.
(end of abstract)

Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd. - Philadelphia, PA, US
Inventor: Nobuto Yamamoto
USPTO Applicaton #: 20060014143 - Class: 435005000 (USPTO)

Full Patent Description

09-14-2008, 01:27 PM	#7
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	Nobuto Yamamoto's patent application Preparation of potent macrophage activating factors derived from cloned vitamin d binding protein and its domain and their therapeutic usage for cancer, hiv-infection and osteopetrosis USPTO Application #: 20060014143 Title: Preparation of potent macrophage activating factors derived from cloned vitamin d binding protein and its domain and their therapeutic usage for cancer, hiv-infection and osteopetrosis Abstract: Vitamin D-binding protein (Gc protein) and its small domain (approximately ⅕ of the Gc peptide also known as domain III) were cloned via a baculovirus vector. The cloned Gc protein and the cloned domain (Cd) peptide were treated with immobilized β-galactosidase and sialidase to yield macrophage activating factors, GcMAFc and CdMAF, respectively. These cloned macrophage activating factors and GcMAF are to be used for therapy of cancer, HIV-infection and osteopetrosis, and may also be used as adjuvants for [COLOR=blue ! important][COLOR=blue ! important]immunization[/COLOR][/COLOR] and vaccination. (end of abstract) Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd. - Philadelphia, PA, US Inventor: Nobuto Yamamoto USPTO Applicaton #: 20060014143 - Class: 435005000 (USPTO) Full Patent Description __________________ Mom's treatment history (link)